Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pertuzumab
Drug: T-DM1
Drug: Paclitaxel
Drug: Vinorelbine

First Posted Date: 2013-04-18

Last Posted Date: 2021-03-30

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 208

Registration Number: NCT01835236

Locations: 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 68 locations

Cetuximab for Elderly Patients With mCRC

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Cetuximab
Drug: Capecitabine

First Posted Date: 2012-10-31

Last Posted Date: 2017-01-24

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 24

Registration Number: NCT01718808

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Spitalzentrum Biel, Biel, Switzerland

and more 11 locations

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: Orteronel

First Posted Date: 2012-10-16

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 47

Registration Number: NCT01707966

Locations: 🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Universitaetsspital Basel, Basel, Switzerland

and more 12 locations

Therapy De-escalation in Seminoma Stage IIA/B

Phase 2

Active, not recruiting

Conditions: Seminoma

Interventions: Drug: Carboplatin
Radiation: Involved node RT

First Posted Date: 2012-05-08

Last Posted Date: 2024-03-12

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 115

Registration Number: NCT01593241

Locations: 🇩🇪
Berlin Universitätsklinik Charité, Berlin, Germany
🇩🇪
Hamburg Universitätsklinikum - Eppendorf, Hamburg, Germany
🇩🇪
Aachen Universitätsklinik, Aachen, Germany

and more 22 locations

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Nelfinavir
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-03-15

Last Posted Date: 2022-07-07

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 33

Registration Number: NCT01555281

Locations: 🇨🇭
Kantonsspital Olten, Olten, Switzerland
🇨🇭
UniversitätsSpital Zürich, Zürich, Switzerland
🇮🇹
Istituto Europeo di Oncologia IEO, Milano, Italy

and more 8 locations

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Biological: Rituximab
Drug: lenalidomide

First Posted Date: 2011-03-03

Last Posted Date: 2023-06-27

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 154

Registration Number: NCT01307605

Locations: 🇸🇪
University Hospital of Linkoping, Linkoping, Sweden
🇸🇪
Karolinska University Hospital - Huddinge, Stockholm, Sweden
🇸🇪
Sunderbyn Hospital, Lulea, Sweden

and more 30 locations

Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Radiation: radiation therapy

First Posted Date: 2011-01-07

Last Posted Date: 2024-08-28

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 350

Registration Number: NCT01272050

Locations: 🇧🇪
Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium
🇧🇪
Ghent University Hospital, Ghent, Belgium
🇩🇪
University Hospital and Medical Faculty Technical University of Dresden, Dresden, Germany

and more 25 locations

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Metformin

First Posted Date: 2010-11-18

Last Posted Date: 2019-08-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 44

Registration Number: NCT01243385

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Kantonsspital Luzern, Luzerne, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 6 locations

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Mature T-cell and Nk-cell Neoplasms
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Leukemia

Interventions: Drug: bortezomib
Drug: nelfinavir mesylate

First Posted Date: 2010-07-19

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 18

Registration Number: NCT01164709

Locations: 🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland
🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

and more 1 locations

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: fulvestrant
Drug: selumetinib

First Posted Date: 2010-07-12

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 46

Registration Number: NCT01160718

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
City Hospital Triemli, Zurich, Switzerland

and more 14 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy